PPARα/γ Expression and Activity in Mouse and Human Melanocytes and Melanoma Cells

• Published in: Pharmaceutical research Vol. 25; no. 6; pp. 1327 - 1333
• Main Authors: Eastham, Linda L., Mills, Caroline N., Niles, Richard M.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.06.2008; Springer
• Subjects: Biochemistry; Biological and medical sciences; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; General pharmacology; Medical Law; Medical sciences; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacy; Research Paper; melanoma; PPAR expression; melanocytes; growth inhibition; Human; Pharmaceutical technology; Rodentia; Malignant tumor; In vitro; PPAR-α receptor; Vertebrata; Mammalia; Mouse; Animal; Malignant melanoma; Cancer
• ISSN: 0724-8741; 1573-904X
• DOI: 10.1007/s11095-007-9524-9

Purpose We examined the expression of PPARs and the effects of PPARα and PPARγ agonists on growth of mouse and human melanocytes and melanoma cells. Methods PPARα,β, and PPARγ mRNA qualitative expression in melan-a mouse melanocytes, B16 mouse melanoma, human melanocytes, and A375 and SK-mel28 human melanoma cells was determined by RT-PCR, while quantitative PPARα mRNA levels were determined by QuantiGene assay. PPARα and PPARγ protein was assessed by Western blotting. The effect of natural and synthetic PPAR ligands on cell growth was determined by either hemocytometer counting or crystal violet assay. PPAR transcriptional activity was determined by a PPRE-reporter gene assay, while knockdown of PPARα expression was achieved by transient transfection of siRNA. Results Both mouse and human melanoma cells produced more PPARα and PPARγ protein compared to melanocytes. PPARα mRNA levels were elevated in human melanoma cells, but not in mouse melanoma cells relative to melanocytes. Silencing of PPARα in human melanoma cells did not alter cell proliferation or morphology. PPARγ-selective agonists inhibited the growth of both mouse and human melanoma cells, while PPARα-selective agonists had limited effects. Conclusion Increased expression of PPARα in melanoma relative to melanocytes may be a common occurrence, however its biologic significance remains to be determined. PPARγ agonists may be useful for arresting the growth of some melanomas.